Characterizing the emergence of amyloid and tau burden in Down syndrome
Authors:
Open Access
- 29 August 2023
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (1) , 388-398
Abstract
INTRODUCTION: Almost all individuals with Down syndrome (DS) will develop neuropathological features of Alzheimer's disease (AD). Understanding AD biomarker trajectories is necessary for DS‐specific clinical interventions and interpretation of drug‐related changes in the disease trajectory.METHODS: A total of 177 adults with DS from the Alzheimer's Biomarker Consortium‐Down Syndrome (ABC‐DS) underwent positron emission tomography (PET) and MR imaging. Amyloid‐beta (Aβ) trajectories were modeled to provide individual‐level estimates of Aβ‐positive (A+) chronicity, which were compared against longitudinal tau change.RESULTS: Elevated tau was observed in all NFT regions following A+ and longitudinal tau increased with respect to A+ chronicity. Tau increases in NFT regions I‐III was observed 0–2.5 years following A+. Nearly all A+ individuals had tau increases in the medial temporal lobe.DISCUSSION: These findings highlight the rapid accumulation of amyloid and early onset of tau relative to amyloid in DS and provide a strategy for temporally characterizing AD neuropathology progression that is specific to the DS population and independent of chronological age.Highlights: Longitudinal amyloid trajectories reveal rapid Aβ accumulation in Down syndrome NFT stage tau was strongly associated with A+ chronicity Early longitudinal tau increases were observed 2.5–5 years after reaching A+Keywords
This publication has 50 references indexed in Scilit:
- Age dependence of brain β-amyloid deposition in Down syndromeNeurology, 2015
- Symptom onset in autosomal dominant Alzheimer diseaseNeurology, 2014
- Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndromeBrain, 2014
- Brain β-amyloid load approaches a plateauNeurology, 2013
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseNew England Journal of Medicine, 2012
- Using Positron Emission Tomography and Carbon 11–Labeled Pittsburgh Compound B to Image Brain Fibrillar β-Amyloid in Adults With Down SyndromeArchives of Neurology, 2011
- High Striatal Amyloid β-Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation TypesArchives of Neurology, 2009
- Carbon 11–Labeled Pittsburgh Compound B Positron Emission Tomographic Amyloid Imaging in Patients With APP Locus DuplicationArchives of Neurology, 2008
- Genetic and host factors for dementia in Down's syndromeThe British Journal of Psychiatry, 2002
- Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's DiseaseNew England Journal of Medicine, 1989